Summary
A phase II trial of idarubicin was performed in 24 patients with advanced lymphoma. The drug was administered in a dose of 10–15 mg/m2 i.v. or 15–70 mg/m2 p.o. (single dose) every 3 weeks. There were four partial responses and four minor responses. All but one of the responders had received prior doxorubicin therapy. The toxicities were myelosuppression, nausea and vomiting, and alopecia. Two patients with compromised cardiac function were observed to have further deterioration in the ejection fraction as measured by gated cardiac scan after idarubicin therapy. Further assessment of the activity of idarubicin against lymphoma is recommended in less heavily pretreated patients. The cardiac toxicity should be carefully monitored in future studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arcamone F, Bernardi L, Giardino P, Di Marco A, Casazza AM, Pratesi G (1976) Synthesis and anti-tumour activity of 4-demethoxydaunorubicin, 4-demethoxy-7-9-diepidaunorubicin and their beta anomers. Cancer Treat Rep 60:829
Berman E, Wittes RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, Williams L, Baratz R, Young CW (1983) Phase I clinical pharmacology studies of intravenious and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 43:6096–6101
Bonfante V, Ferrai L, Villani F, Bonnadonna G (1983) Phase I study of 4-demethoxydaunorubicin. Invest New Drugs 1: 161
Broggini M, Italia C, Colombo T, Marmonti L, Donelli MG (1984) Activity and distribution of intravenous and oral 4-demethoxydaunorubicin in murine experimental tumours. Cancer Treat Rep 68:739
Carella AM, Santini G, Martinengo AM, Congiu A, Nati S, Marmont AM (1985) Idarubicin alone or in combination with cytarabine and etoposide (3+3+5) in acute non-lymphoblastic leukaemia. Proc 14th Int Congress Chemotherapy. Kyoto, Japan (Abst no. WS 4-16)
Casazza AM (1979) Experimental evaluation of anthracycline analogues. Cancer Treat Rep 63:835
Casazza AM, Bertazzoli C, Pratesi G, Bellini O, Di Marco A (1979) Anti-leukaemia activity and cardiac toxicity of 4-demethoxydaunorubicin. Proc Am Assoc Cancer Res 20:16
Cassaza AM, Pratesi G, Giuliani F, Di Marco A (1980a) Anti-leukaemic activity of 4-demethoxydaunorubicin in mice. Tumori 66:549
Casazza AM, Di Marco A, Bonadonna G, Bonfante V, Bertazzoli C, Bellini O, Pratesi G, Sala L, Ballerini L (1980b) Effects of modification in position 4 of the chromophore or in the position 4′ of the aminosugar on the antitumour activity of anthracyclines. In: Crooke ST, Reich SD (eds) Anthracyclines: current status and new development. Academic Press, New York, p 430
Coonley CJ, Warrell Jr RP, Straus DJ, Young CW (1983) Clinical evaluation of 4-demethoxydaunorubicin in patients with advanced malignant lymphoma. Cancer Treat Rep 67: 949
Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelemann R, Budman D, Schulman P, Baratz R, Williams L, Clarkson BD, Young CW (1985) Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukaemia. Cancer Res 45:1408
Di Marco A, Casazza AM, Pratesi G (1977) Antitumour activity of 4-demethoxydaunorubicin administered orally. Cancer Treat Rep 61:893
Di Marco A, Zunio F, Casazza AM (1978) Comparison of biochemical and biological methods in evaluation of new anthracycline drugs. Antibiot Chemother 23:12
Eridani S, Pearson TC, Slater NGP, Singh AK (1985) Idarubicin (NSC 256-439) in the treatment of acute leukaemia and lymphoma: a pilot study. Proceedings of the European Congress of Clinical Oncology, Stockholm, Sweden (Abstract 494)
Kaplan S, Martini A, Varini M, Togni P, Cavalli F (1982) Phase I trial of 4-demethoxydaunorubicin with single IV dose. Eur J Cancer Clin Oncol 12:1303
Lopez M, Lazzano B, Di Lauro L, Papalab P, Ganzina F, Di Pietro N (1985) Activity of oral idarubicin in non-Hodgkin's lymphomas. European Congress of clinical Oncology, Stockholm, Sweden (Abstract 755)
World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO, Geneva (WHO offset publications no. 48)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gillies, H., Liang, R., Rogers, H. et al. Phase II trial of idarubicin in patients with advanced lymphoma. Cancer Chemother. Pharmacol. 21, 261–264 (1988). https://doi.org/10.1007/BF00262782
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00262782